GSK and Hansoh's experimental bone cancer drug delayed progression in a late-stage China study

Reuters reports that an experimental bone cancer drug being developed by GSK and Hansoh helped patients live longer without the disease worsening, according to data presented by researchers at a medical meeting. Bloomberg reports GSK also presented promising results in ovarian and lung cancers at the European Society for Medical Oncology meeting.